SHELTON, Conn.—May 28, 2025—Intensity Therapeutics, Inc. (NASDAQ: INTS), a late-stage biotechnology company developing immune-based, intratumoral cancer therapies, today announced a partnership with model, author, executive producer, speaker, and breast cancer survivor Kristen Handy. Together, they will create patient-focused educational resources on emerging treatment options for early-stage breast cancer.
Survivor Advocate to Develop Educational Film and Materials
Kristen Handy—whose award-winning novel Walk Beside Me inspired the Palme d’Or–winning film Hello Beautiful—has long championed breast cancer awareness. Diagnosed in 2012, Handy brings firsthand experience with the complex decisions faced by newly diagnosed patients.
“Earlier this year, I discovered Intensity Therapeutics and their promising data on a novel tumor-injectable therapy that offers hope to those grappling with the challenges of breast cancer treatment,” Handy said. “I am passionate about supporting women diagnosed with early-stage breast cancer and look forward to developing educational resources about treatment options and emerging therapies. Stories like Hello Beautiful serve as beacons of hope, and innovative therapies such as INT230-6 promise more effective and compassionate care.”
Company Mission and Ongoing Clinical Trial
Intensity Therapeutics focuses on intratumoral experimental agents designed to kill tumors and enhance immune recognition of cancer cells. Its lead candidate, INT230-6, is currently under evaluation in the Phase 2 INVINCIBLE-4 trial for patients with triple-negative breast cancer receiving immuno-chemotherapy prior to surgery.
“Working with Kristen Handy is a natural fit,” said Lewis H. Bender, Founder and CEO of Intensity Therapeutics. “Her journey reflects the fear, uncertainty, and tough choices many women face. We share her commitment to improving outcomes and safety for early-stage breast cancer patients. Through our collaboration, we aim to help pre-operative cancer patients worldwide understand the potential of new treatments as we advance drug development.”
Joint Appearance at ASCO 2025
Both Handy and Bender will attend the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, held May 30–June 3 at McCormick Place in Chicago. There, they will present educational sessions and engage with patients, caregivers, and oncologists to discuss intratumoral therapies and the future of breast cancer care.
Related topics:
- Dale Griffith Shares Good News In Cancer Fight
- Charity Gets £25k To Support Women With Breast Cancer
- India’s First Robot-Assisted Heart, Breast Surgery In Delhi
